Inhibitor Therapeutics, Inc. Income Statement
INTI|7 years of annual SEC 10-K data (FY2014-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$0
FY2021
Gross Profit
N/A
FY2021
Operating Income
-$325,395
FY2021
Net Income
-$298,632
FY2021
Inhibitor Therapeutics, Inc. reported $0 in revenue and $298,632 in net loss for FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -856.15 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $320.5K | $873.7K | $1.9M | $2.9M | $4.4M | $2.3M | $1.5M |
| R&D Expense | $4.9K | $185.3K | $2.6M | $2.2M | $2.6M | $1.7M | $2.4M |
| Operating Income | -$325.4K | -$1.1M | -$4.6M | -$5.1M | -$7.0M | -$3.9M | -$3.9M |
| Interest Expense | $14.8K | - | - | - | - | - | $37.5K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$298.6K | -$1.1M | -$4.6M | -$5.1M | -$7.0M | -$3.9M | -$4.0M |
| EPS (Diluted) | $0.00 | -$0.01 | -$0.01 | -$0.02 | -$0.02 | -$0.04 | -$0.10 |
| Shares Outstanding | 373.6M | 370.4M | 369.6M | 353.4M | 245.4M | 211.4M | 18.9M |